Genome Editing/Gene Editing

The first team to disable a disease gene directly in a person through an infusion of the genome editor CRISPR reported yesterday that levels of the toxic protein…

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome…

In February last year, Doherty - now about age 65 - began to experience the same early breathing symptoms his father had had. As an avid hiker who has trekked the…

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based…

Patrick Doherty had always been very active. He trekked the Himalayas and hiked trails in Spain. But about a year and a half ago, he noticed pins and needles in his…